Gartner Inc vs Recursion Pharmaceuticals Inc — how do they compare? Gartner Inc trades at $137.47 (market cap $9.44B), while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.53B). The key difference: Gartner Inc is far larger — about 6.2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| IT | RXRX | |
|---|---|---|
Market Cap | $9.44B | $1.53B |
Sector | Technology | Health |
52-Week High | $357.98 | $6.79 |
52-Week Low | $125.68 | $2.84 |
Enterprise Value | $11.04B | $946.50M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Trailing returns across standard periods
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →